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Abstract
Background: Antibodies against Ro-52 have been described in patients with a broad spectrum of
autoimmune disease, most commonly in association with anti-Ro-60 in systemic lupus
erythematosus and Sjogrens syndrome. However, in inflammatory myositis anti-Ro-52 is frequently
present without anti-Ro-60 and is closely linked to the presence of aminoacyl-tRNA synthetase
(aats) antibodies. To date there have been no comprehensive reports on the frequency of anti-Ro-
52 in systemic sclerosis (SSc), a disease characterised by hallmark autoantibodies that occur in non-
overlapping subsets. Clinically, each antibody-defined group has a distinct pattern of organ
involvement, some featuring myositis.
Objectives: To determine the frequency of anti-Ro-52 in serologically defined groups of SSc
patients and to investigate a possible link with myositis-associated autoantibodies.
Methods: Serum samples from 1010 patients with SSc and 55 and 32 patients with anti-aats and
anti-Ku respectively were tested for the presence of anti-Ro-52 using a commercial ELISA.
Results: The prevalence of anti-Ro-52 was 15–38% in nine of the eleven sub-groups. There were
no significant differences in mean anti-Ro-52 levels in these groups with the exception of that
defined by the presence of anti-U1-RNP. In the remaining groups defined by anti-Ro-60 and anti-
aats, anti-Ro-52 was present in 92% and 100% respectively. In sera from non-SSc patients with anti-
aats, anti-Ro-52 was detected in 64%.
Conclusion: Anti-Ro-52 is present throughout the SSc population. It is neither more prevalent in
the myositis-associated antibody groups nor does it segregate with any other major SSc-specific
autoantibodies. The co-existence of anti-Ro-52 with both anti-Ro-60 and anti-aats is confirmed.
Introduction
Antibodies to the 52 kDa protein Ro-52 were first
described in 1988 in addition to antibodies to Ro-60 and
La in the serum of patients with Sjogrens syndrome (SS)
[1]. Unlike antibodies to Ro-60 and La, they do not pro-
duce any specific anti-nuclear antibody staining pattern
by indirect immunofluorescence, any precipitin line by
immunodiffusion or electroimmunodiffusion, or positive
results in enzyme-linked immunosorbent assays (ELISA)
containing native antigen [2]. Anti-Ro-52 is mainly
Published: 6 March 2009
Journal of Autoimmune Diseases 2009, 6:2 doi:10.1186/1740-2557-6-2
Received: 7 November 2008
Accepted: 6 March 2009
This article is available from: http://www.jautoimdis.com/content/6/1/2
© 2009 Parker et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Autoimmune Diseases 2009, 6:2 http://www.jautoimdis.com/content/6/1/2
Page 2 of 6
(page number not for citation purposes)
detected in the diagnostic laboratory because of the inclu-
sion of recombinant antigen in commercial ELISA and
immunoblotting assays [3].
Antibodies to Ro-52 have been shown to be present with
anti-Ro-60 (with or without co-existing anti-La) at a high
frequency in sera from patients with systemic lupus ery-
thematosus (SLE) and SS [4,5] and one area of interest has
centred on their possible pathogenic role in the develop-
ment of congenital heart block, a complication of the neo-
natal lupus syndrome [6]. Sera that are monospecific for
anti-Ro-52 (ie without anti-Ro-60) have also been
described in SS and SLE, but only at a low frequency [2,5].
It has been reported that anti-Ro-52 (mainly monospe-
cific) is present in a large proportion of patients with
autoimmune myositis and is closely associated with the
myositis-specific anti-aminoacyl-tRNA synthetase (aats)
antibodies [7,8]. Neither anti-Ro-60 nor anti-La exhibits
this association with anti-aats. This finding has lead to
anti-Ro-52 being termed a myositis-associated autoanti-
body (MAA) [9,10].
SSc is a heterogeneous autoimmune rheumatic disease of
unknown aetiology characterised by thickening and fibro-
sis of the skin and other organs [11]. Virtually all patients
have autoantibodies to specific cellular components that
are mutually exclusive and correlate with well docu-
mented clinical subsets of disease including features of
overlap with other connective tissue diseases such as pol-
ymyositis (PM) [12]. In this study we have assessed SSc
patients characterised for a range of specific antibodies,
and additional groups of patients with antibodies to aats
and the connective tissue disease associated antibody Ku
for the presence of anti-Ro-52. There are currently no




Serum samples were from 1010 patients diagnosed by an
experienced rheumatologist at the Royal Free Hospital, a
major tertiary referral centre for SSc, according to the pre-
liminary ACR criteria [13]. All SSc patients had been con-
sented for participation in research studies, approved by
the local ethics committee. Antibody groups represented
were as follows: anti-centromere (ACA) n = 197, anti-
topoisomerase (ATA) n = 210, anti-RNA polymerase III
(ARA) n = 207, anti-fibrillarin (AFA) n = 48, anti-Pm-Scl
n = 49, anti-U1-RNP n = 58, anti-Ro-60 n = 13, anti-aats
(4 anti-Jo-1, 1 anti-PL7, 1 anti-PL12) n = 6, and anti-Ku n
= 5. In addition, two further groups were formed from SSc
patients with no defined antibody (NDA) n = 173, and
those whose sera produced an ANA pattern of fine speck-
led nucleoplasmic staining with additional homogeneous
nucleolar staining (fsnu) n = 44. The latter group repre-
sented a heterogeneous population including patients
with anti-Th-RNP. All sera were tested for anti-nuclear
antibodies by indirect immunofluorescence on HEp-2 cell
substrate (Bion inc, Illinois, USA) this was the only
method used to define the patients with ACA. The pres-
ence of other antibodies was confirmed by counterimmu-
noelectrophoresis and radioimmunoprecipitation as
previously described [14,15]. The antibody frequencies
represented in this study do not reflect the prevalence of
each antibody type in the SSc patient population as a
whole. The samples were selected from a bank of frozen
samples stored according to antibody type with patients
having no defined specific antibody being over repre-
sented.
Following initial analysis a number of sera from non-SSc
patients were assessed for presence of anti-Ro-52 to pro-
vide additional data for analysis of association with anti-
aats and anti-Ku, two under represented antibodies in the
selected SSc population. Additional sera tested were from
48 patients with antibodies to aats (36 anti-Jo-1, 8 anti-
PL7, 4 anti-PL12) and 32 patients positive for anti-Ku
antibodies.
Anti-Ro-52 ELISA
Anti-Ro-52 was detected by ELISA using purified recom-
binant Ro-52 (Quanta Lite SS-A 52 ELISA, INOVA Diag-
nostics, Inc. San Diego, USA) and was performed in
accordance with the manufacturer's instructions using the
recommended cut-off of 20 U/ml (also shown to be
appropriate by local validation (data not shown)).
Statistical analysis
Statistical analysis was performed using SPSS v 11.0 soft-
ware. Significant differences in mean anti-Ro-52 levels for
the eleven SSc antibody groups, and the extra anti-aats
and anti-Ku groups, were determined using one-way anal-
ysis of variance (ANOVA) with post-hoc Bonferroni cor-
rection. Significant differences were confirmed with the
Mann-Whitney U-test. A probability value of < 0.05 was
taken to denote statistical significance in all cases.
Results
Sera from 1010 SSc patients divided into eleven groups
based on antibody serology were tested for the presence of
anti-Ro-52. The overall frequency of anti-Ro-52 in this
selected population was 27% (Table 1).
Anti-Ro-52 was present in patients with the major SSc-
specific antibodies ACA, ATA and ARA at frequencies of
28%, 19% and 25% respectively with all three groups hav-
ing a mean anti-Ro-52 level of 22 U/ml. In smaller groups
including the minor SSc-specific antibodies AFA, anti-Pm-
Scl and the less specific anti-U1-RNP, anti-Ro-52 was
present at 15%, 33% and 38%. Two further heterogene-Journal of Autoimmune Diseases 2009, 6:2 http://www.jautoimdis.com/content/6/1/2
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ous groups, those without any of the above antibodies but
producing a speckled nucleoplasmic and nucleolar ANA
pattern and known to contain a percentage of anti-Th-
RNP (fsnu) and, with respect to the RFH cohort as a
whole, a disproportionately large group of patients with
none of the above antibodies or any unifying ANA pattern
(NDA) were found to have frequencies of anti-Ro-52 of
32% and 28% respectively. Finally in the three small cate-
gories the results were as follows: 13 patients constituted
a group where the only identified antibody was anti-Ro-
60, 12/13 (92%) were positive for anti-Ro-52. Anti-Ro-60
was also present in a further 19 patients included in other
serological groups because of the presence of a more spe-
cific antibody. As with those forming the anti-Ro-60
group, 92% of these were positive for anti-Ro-52. Subse-
quent statistical analysis of the remaining ten groups was
not significantly altered by the inclusion or exclusion of
these additional nineteen patients. Sera from six SSc
patients positive for anti-aats were all positive for anti-Ro-
52 and three out of five anti-Ku positive sera were positive
for anti-Ro-52.
Comparisons of mean anti-Ro-52 values showed the anti-
Ro-60 group had significantly higher levels than all other
antibody groups except anti-aats – this small group had
significantly higher anti-Ro-52 concentrations than all the
remaining groups except anti-Ku. There were no signifi-
cant differences in anti-Ro-52 levels for the rest of the
groups (figure 1) apart from with the anti-U1-RNP group
which had significantly different levels to the ACA, ATA,
ARA, AFA and NDA groups but not the anti-Pm-Scl, anti-
Ku and fsnu groups.
To further investigate the association of anti-Ro-52 with
the small anti-aats and anti-Ku groups we tested sera from
an additional 48 patients positive for anti-aats and a fur-
ther 32 sera from anti-Ku positive patients, none of whom
were classified as having SSc. Sixty four percent of the anti-
aats sera and 28% of those with anti-Ku were positive for
anti-Ro-52 (Table 1). The mean levels of anti-Ro52 in the
anti-aats patients remained significantly higher than those
seen overall in the SSc patient groups whereas the anti-Ku
association with anti-Ro-52 was indistinguishable from
the SSc groups (with the exception of the anti-Ro-60 and
anti-aats groups).
Table 1: Frequency and mean level of anti-Ro-52 in patients tested
Antibody Group Number of patients Anti-Ro-52 positive (%) Mean anti-Ro52 level (U/ml)
ACA 197 28 22
AFA 48 15 18
ARA 207 25 22
ATA 210 19 22
fsnu 44 32 26
Anti-aats 6 100 109
Anti-Ku 56 0 4 9
NDA 173 28 31
Anti-Pm-Scl 49 33 34
Anti-U1-RNP 58 38 50
Anti-Ro-60 13 92 121
Total SSc 1010 27 28
Anti-aats (non-SSc) 55 64 78
Anti-Ku (non-SSc) 32 28 33Journal of Autoimmune Diseases 2009, 6:2 http://www.jautoimdis.com/content/6/1/2
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Anti-Ro-52 levels in 11 serologically defined groups of SSc patients and 2 additional non-SSc groups (anti-aats and anti-Ku anti- bodies) Figure 1
Anti-Ro-52 levels in 11 serologically defined groups of SSc patients and 2 additional non-SSc groups (anti-aats 
and anti-Ku antibodies). Boxes show interquartile ranges, lines within the boxes indicate median values and lines outside 
the boxes indicate maximum and minimum values excluding outliers. (See table 1 for numbers of patients in each group).
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Discussion
The majority of work to elucidate clinical correlations of
anti-Ro-52 has focused on patients with SLE, SS and
myositis. Similarly, associations with anti-Ro-60 and anti-
aats have been well documented. However, there have
been relatively few studies addressing the frequency of
this antibody in SSc and no comprehensive reports assess-
ing associations of anti-Ro-52 with the specific autoanti-
bodies that are characteristic of SSc. Initially it was
suggested that there was no reactivity of sera from SSc
patients with recombinant anti-Ro-52 [16]. Subsequently,
reports on the presence and frequency of anti-Ro-52 have
provided conflicting results [2,5,8,17,18]. In this study we
analysed sera from a substantial cohort of SSc patients
representing the entire spectrum of disease, sub-divided
into 11 groups by autoantibody profile. Anti-Ro-52 was
found to be present at a frequency of at least 15% in all
antibody groups tested. The overall frequency of anti-Ro-
52 appears to be greater than previously described [8,18].
Consistent with previous observations, anti-Ro-52 was
present at high frequency in the group of 13 patients in
whom the only identified antibody was anti-Ro-60 [5].
The co-existence of anti-Ro-52 with the myositis-specific
aats antibodies was also confirmed. We were able to
extend the initial data from a small number of SSc
patients by testing additional sera positive for anti-aats
and demonstrating a high degree of association with anti-
Ro-52, the results being comparable to previous reports
[7-9]. As with anti-Ro-60 the reason for the high fre-
quency of anti-Ro-52 in anti-aats positive sera is unknown
but it is not due to cross-reactivity between anti-Jo-1 and
Ro-52 [7].
In the nine other groups of SSc patients the frequency of
anti-Ro-52 varied from 15% in the AFA group to 38% in
the anti-U1-RNP group. When detected by traditional
methods, as described in this study, it is a characteristic
feature of SSc that each patient will typically have only
one of a series of hallmark autoantibodies that therefore
occur in a mutually exclusive fashion. However, a recent
study employing an addressable laser bead immunoassay
to analyse autoantibodies in the sera of patients with
autoimmune myositis highlighted unusual antibody
combinations not previously described [19]. Eventually
the wider application of sensitive multiplex methods
could confirm whether there is an, as yet, undescribed
overlap between the antibody populations. Currently
each antibody has been shown to be associated with a dis-
ease phenotype and can predict features such as age of
onset, extent of skin, and type of organ involvement. The
major SSc-specific autoantibodies ACA, ATA and ARA are
predictive of the clinical manifestations of limited disease
with minimal internal organ involvement, pulmonary
fibrosis and renal involvement respectively. As there is no
significant difference in the level and frequency of anti-
Ro-52 in these three groups it is clear that there is neither
an association with any of these antibodies nor, by infer-
ence, the clinical outcomes they predict.
As a consequence of the association of anti-Ro-52 with
anti-aats and other studies that link myositis-specific anti-
Mi-2 and anti-signal recognition particle (SRP) to anti-Ro-
52, [9] it was hypothesised that the three antibody groups
described as having an increased incidence of muscle
involvement (AFA, anti-Pm-Scl, anti-U1-RNP) might
show an increased association of anti-Ro-52 compared to
the major SSc-specific antibody groups (ACA, ATA, ARA)
where myositis is not a prominent feature [12]. The results
from this study do not support this proposal.
Anti-Pm-Scl is associated with an overlap syndrome in
which up to 80% of SSc patients have inflammatory mus-
cle disease [20]. We did not find any significant difference
between the anti-Ro-52 levels in anti-Pm-Scl positive
patients and the major SSc antibodies. However, Frank et
al reported that the response to Ro-52 was clearly present
in anti-Pm-Scl patients while it was rare in ACA and ATA
positive SSc patients. It was suggested that detection of
anti-Ro-52 may prove useful in discriminating between
patients in these antibody groups [8]. This view is not
upheld by our findings.
This study also expands the limited data available on anti-
Ro-52 in AFA positive patients. Myositis has been shown
to be a prominent feature of patients with this antibody.
Keonig et al detected anti-Ro-52 in six of fourteen autoim-
mune myositis patients with AFA and in a previous study
from this centre 50% of SSc patients with AFA were shown
to have myositis [19,21]. There was no association of anti-
Ro-52 with AFA, indeed the mean anti-Ro-52 level in the
AFA group was lower than in the non-myositis-associated
antibody groups.
The results obtained for anti-U1-RNP show a bimodal dis-
tribution for anti-Ro-52 with a number of patients having
extremely high levels of the antibody. This is likely to
account for the higher mean anti-Ro-52 value observed
for the anti-U1-RNP group and the subsequent significant
differences from the majority of the SSc antibodies not
seen for any other antibody group except anti-Ro-60 or
anti-aats. We were unable to determine any specific rea-
son to explain this interesting finding.
Only five anti-Ku positive patients were identified in the
SSc population and three were positive for anti-Ro-52.
Anti-Ku was originally described in Japanese patients with
SSc/PM overlap, but in the North American population it
appears to be present in a more SLE-like disease [22] The
anti-Ku positive patients had higher anti-Ro-52 valuesJournal of Autoimmune Diseases 2009, 6:2 http://www.jautoimdis.com/content/6/1/2
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than the majority of the other SSc antibody groups (figure
1) but when an expanded number of non-SSc anti-Ku pos-
itive sera were analysed there was no significant difference
in anti-Ro-52 levels to the SSc population (with the excep-
tion of the anti-aats and anti-Ro-60 groups).
Anti-Ro-52 was also present in the two miscellaneous
groups. The NDA and fsnu groups in this study were over
represented compared to the Royal Free Hospital cohort
overall as it was felt that these were possible candidate
patients for the presence of anti-Ro-52, there being no
other defining antibody detected. The fsnu group was
known to contain a proportion of anti-Th-RNP positive
patients but due to inconsistent detection by radioimmu-
noprecipitation, this could not be classed as a homogene-
ous population. Anti-Ro-52 was detected in 28% and 32%
respectively and these values were not statistically differ-
ent from any other group (except anti-Ro-60 and anti-
aats). Of note anti-Ro-52 was the only detectable anti-
body in 48 patients in the NDA group.
Conclusion
The data presented here demonstrate that anti-Ro-52 is
prevalent throughout the SSc population and does not
segregate with any of the major SSc-specific autoantibod-
ies. We confirm the association with both anti-Ro60 and
aats antibodies but find no evidence that anti-Ro-52 is
found at a higher frequency in SSc patients with myositis-
associated antibodies. These findings support the hypoth-
esis that anti-Ro-52 is a general serum marker with limited
linkage to a myositis phenotype or other clinical manifes-
tations of SSc.
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